Rintatolimod added to pembrolizumab and cisplatin yields 50% response rate in recurrent ovarian cancer
read at onclive ↗Positive readoutPositive
A clinical study evaluated the combination of rintatolimod, pembrolizumab and cisplatin in patients with recurrent ovarian cancer.
The regimen produced an objective response rate of 50%, indicating that half of the participants experienced measurable tumor shrinkage.
These results are preliminary, and further trials will be needed to confirm efficacy and safety before the approach can be adopted more widely.
source
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer”
read at onclive ↗
comments(0)
5-min edit window · permanent after that